Clinical Report: Efficacy of Trametinib as a Second-Line Treatment in NSCLC
Overview
This retrospective study evaluates trametinib's efficacy and safety as a second-line treatment for advanced NSCLC with KRAS G12C mutations. The findings indicate a 27.8% objective response rate and manageable toxicity, highlighting potential clinical factors influencing treatment response.
Background
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality, with KRAS mutations being prevalent among advanced cases. The KRAS G12C mutation is particularly significant, as it has been targeted by specific inhibitors, yet access to these therapies can be limited. Thus, exploring alternative treatments like trametinib is essential for improving patient outcomes.
Data Highlights
Parameter
Value
Objective Response Rate (ORR)
27.8% (5/18)
Disease Control Rate (DCR)
72.2% (13/18)
Median Progression-Free Survival (PFS)
3.8 months (95% CI: 2.9–4.7 months)
Median Overall Survival (OS)
8.6 months (95% CI: 6.4–10.8 months)
Common Adverse Reactions
Rash (35.0%), Diarrhea (25.0%), Fatigue (20.0%)
Key Findings
The ORR for trametinib was 27.8% among patients with KRAS G12C mutations.
The DCR was 72.2%, indicating substantial disease control.
Median PFS was 3.8 months, while median OS was 8.6 months.
Patients without bone metastasis had a significantly higher ORR (35.7%) compared to those with bone metastasis (0%).
PD-L1 expression ≥1% was associated with a higher DCR (81.8% vs. 50.0%).
Adverse reactions were generally manageable, with no grade 4 or higher reactions reported.
Clinical Implications
Trametinib may serve as a viable second-line treatment option for patients with advanced NSCLC harboring KRAS G12C mutations, especially when specific inhibitors are unavailable. Clinicians should consider the presence of bone metastasis and PD-L1 expression when evaluating treatment response.
Conclusion
Trametinib demonstrates anti-tumor activity and manageable toxicity in advanced NSCLC with KRAS G12C mutations. Further validation through larger prospective studies is warranted to confirm these findings.
